NCT ID | NCT03241810 |
Title | Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC) |
Recruitment | Recruiting |
Gender | female |
Phase | Phase II |
Variant Requirements | yes |
Sponsors | Merrimack Pharmaceuticals |
Indications | |
Therapies | |
Age Groups: | adult senior |